ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
CHI3L1 is a diagnostic biomarker involved in immune infiltration of gastric cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aims to investigate the expression of Chitinase-3-like protein-1 (CHI3L1) in gastric cancer (GC) tissues and serum from patients, analyze the correlation between CHI3L1 expression and GC patients' clinicopathological parameters, evaluate its impact on patient prognosis and the tumor immune microenvironment, and explore the potential of CHI3L1 as a diagnostic biomarker in GC. MATERIALS AND
methodsThe expression of CHI3L1 in GC was investigated using data from The Cancer Genome Atlas (TCGA) and TIMER databases. The association between CHI3L1 expression and prognosis in GC patients was analyzed through the TCGA database. Serum samples were collected from 87 patients with GC, 38 patients with gastric precancerous lesions, and 42 healthy volunteers. The levels of CHI3L1 in serum specimens were measured via chemiluminescent immunoassay (CLIA), and the receiver operating characteristic (ROC) curve was employed to further evaluate the diagnostic efficacy of CHI3L1. Gene Set Enrichment Analysis (GSEA) was performed using gene sets from the Molecular Signatures Database (MsigDB). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on correlated genes obtained from the LinkedOmics database. Additionally, the CIBERSORT algorithm was applied to investigate the correlation between CHI3L1 and gastric cancer immune infiltration, aiming to explore the potential mechanisms of CHI3L1 in GC.
resultsCHI3L1 expression was significantly upregulated in GC (P < 0.05) and exhibited strong correlations with GC subtypes, tumor differentiation grade, primary tumor status, regional lymph node metastasis, distant metastasis, clinical stage, Borrmann classification, and tumor size (all P < 0.05). Prognostic analysis revealed correlations between patient survival and age, primary tumor status, regional lymph node metastasis, distant metastasis, clinical stage, new tumor events, and residual tumor (all P < 0.05). Notably, CHI3L1 demonstrated high diagnostic efficacy for GC (In the TCGA database: AUC = 0.861, P < 0.0001; For the serum samples: AUC = 0.932, P < 0.0001). Gene Set Enrichment Analysis (GSEA) suggested that CHI3L1 is involved in multiple oncogenic signaling pathways, including the NF-κB, IL-17, and ECM-receptor interaction pathways. Functional enrichment analysis further linked CHI3L1 to inflammatory response and immune regulation, while immune infiltration analysis via CIBERSORT indicated significant correlations between CHI3L1 expression and infiltration levels of multiple immune cell types.
conclusionsCHI3L1, an oncogenic glycoprotein, is highly expressed in GC and involved in immune infiltration, holding promise as a diagnostic biomarker for GC.
Indexed as
Identifiers
41102516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.